Business Daily Media

.

.

Nasodine Research Points to Potential Role in CRS


Firebrick Pharma Limited (ASX: FRE) is pleased to announce the publication of new research into Nasodine® Nasal Spray identifying its potential in the management of chronic rhinosinusitis (CRS).

“To date, the development of Nasodine has focused on treatment of the common cold, which is generally caused by viruses,” said Firebrick Executive Chairman, Dr Peter Molloy. “This new research suggests it could also have a future role in bacterial CRS.”

CRS is an infection of the sinuses generally caused by strains of Staph. aureus. It is difficult to treat and becomes chronic because of the bacterium’s ability to shield itself from antibiotics and host immune responses by forming a protective ‘biofilm’.

The research evaluated for the first time the activity of Nasodine against S. aureus biofilms in vitro using a biofilm reactor model. Nasodine demonstrated time and concentration-dependent bacterial killing against intact biofilm with statistically significant reductions in viable bacteria with exposures as brief as 5 min. It consistently eradicated dispersed biofilm within 1 min.

The article concludes: “Nasodine is highly active against biofilms of S. aureus ATCC 6538 in vitro…Nasodine is an effective antibiofilm agent that holds promise for the management of sinonasal biofilms in CRS. Clinical trials are now required to determine whether this product offers clinical benefit for this condition.”

“Our clinical focus continues to be on Nasodine as a treatment for the common cold,” said Dr Molloy. “However, just as we have been exploring Nasodine’s potential in COVID-19, we may now want to consider its future development in CRS.”

Sponsored by Firebrick, the research was conducted at the University of Auckland and has now been published in the prestigious journal, The Laryngoscope1.

About CRS1

Chronic rhinosinusitis (CRS) is one of the most common chronic medical conditions worldwide, affecting all age groups. The estimated incidence of CRS is high: 12.3% in the USA, 10.9% in Europe and 13% in China.

Hale, S.J.M., Lux, C.A., Kim, R., Biswas, K., Tucker, S., Friedland, P., Mackenzie, B.W. and Douglas, R.G. (2023), In vitro Nasodine Can be an Effective Antibiofilm Agent for Biofilms that May Cause CRS. The Laryngoscope. https://doi.org/10.1002/lary.30558

Albu S. Chronic Rhinosinusitis-An Update on Epidemiology, Pathogenesis and Management. J Clin Med. 2020 Jul 18;9(7):2285. doi: 10.3390/jcm907228.

Business Reports

How Biometric Authentication and Verification will Revolutionise Security

Digital transformation is on the rise, yet identity theft, fraud and scams have ballooned in Australia, largely due to the devastating data breaches at Optus, Medibank and other major companies. Businesses should be ramping up ...

A journey from work to home is about more than just getting there – the psychological benefits of commuting that remote work doesn't provide

Gridlock can be therapeutic.mikroman6/Moment via Getty ImagesFor most American workers who commute, the trip to and from the office takes nearly one full hour a day – 26 minutes each way on average, with 7.7% of workers spen...

Tecala Achieves Climate Active Carbon Neutral Standard for Organisations

Leading technology service provider Tecala Group today announced that it has achieved the Climate Active Carbon Neutral Standard for Organisations and is now certified as carbon neutral for its Australian business operations, th...